NasdaqGM - Delayed Quote • USD
Lumos Pharma, Inc. (LUMO)
At close: 3:47 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 5 |
| Avg. Estimate | -1.18 | -0.68 | -2.81 | -2.01 |
| Low Estimate | -1.29 | -1.31 | -4.84 | -2.39 |
| High Estimate | -0.95 | 1.29 | -0.5 | -1.64 |
| Year Ago EPS | -0.89 | -1.09 | -4.18 | -2.81 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 5 |
| Avg. Estimate | 300k | 8.3M | 8.81M | 8.64M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | 1M | 40M | 40M | 39.14M |
| Year Ago Sales | 691k | -- | 2.05M | 8.81M |
| Sales Growth (year/est) | -56.60% | -- | 329.50% | -1.90% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -1.12 | -1.1 | -1.15 | -1.15 |
| EPS Actual | -0.89 | -1.09 | -1.04 | -1.17 |
| Difference | 0.23 | 0.01 | 0.11 | -0.02 |
| Surprise % | 20.50% | 0.90% | 9.60% | -1.70% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -1.18 | -0.68 | -2.81 | -2.01 |
| 7 Days Ago | -1.18 | -0.68 | -2.81 | -2.01 |
| 30 Days Ago | -1.18 | -0.68 | -2.81 | -2.01 |
| 60 Days Ago | -1.01 | -0.2 | -3.33 | -2.62 |
| 90 Days Ago | -1.01 | -0.2 | -3.33 | -2.62 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | LUMO | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -32.60% | -- | -- | 1.50% |
| Next Qtr. | 37.60% | -- | -- | 11.40% |
| Current Year | 32.80% | -- | -- | 5.20% |
| Next Year | 28.50% | -- | -- | 13.40% |
| Next 5 Years (per annum) | 15.20% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/20/2024 |
| Maintains | Oppenheimer: Outperform to Outperform | 3/8/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/8/2024 |
| Maintains | Oppenheimer: Outperform to Outperform | 12/11/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 12/7/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 9/6/2023 |
Related Tickers
GRI GRI Bio, Inc.
0.4374
-2.13%
BRNS Barinthus Biotherapeutics plc
2.5100
-3.46%
CNTB Connect Biopharma Holdings Limited
1.3900
0.00%
INAB IN8bio, Inc.
1.0600
+1.92%
GLUE Monte Rosa Therapeutics, Inc.
5.47
-1.26%
LRMR Larimar Therapeutics, Inc.
6.46
0.00%
ALEC Alector, Inc.
5.25
-1.69%
IMRX Immuneering Corporation
1.5000
-7.98%
KZIA Kazia Therapeutics Limited
0.3890
-1.52%
TBPH Theravance Biopharma, Inc.
9.17
-0.54%